We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
Read MoreHide Full Article
Key Takeaways
Henry Schein's Q2 growth spanned distribution, specialty products and technology businesses.
Henry Schein One's recurring revenues and new Dentrix Ascend customers support a higher-value software mix.
HSIC targets more than $200 million of operating income improvement, but leverage and costs remain risks.
Henry Schein, Inc. (HSIC - Free Report) is showing broader growth and a better earnings outlook, but the investment case is not free of execution risk. Second-quarter gains spanned distribution, specialty products and technology, while management raised its 2026 sales and earnings guidance.
The question is whether that improvement is enough to justify buying now. Relative valuation is supportive, but leverage, customer concentration and a savings plan that is still ramping argue for evidence that margin gains can persist.
HSIC’s Core Businesses Are Showing Better Growth
Second-quarter growth was broad. Global Distribution and Value-Added Services sales rose 6.6%, Global Specialty Products increased 8.7% and Global Technology advanced 8.2%. That mix reduces reliance on any single business line to carry the growth story.
Internal growth was also healthy in key areas. Global Distribution and Value-Added Services posted 4.5% internal growth, while Technology delivered 9.1%, helping management lift its 2026 total sales growth outlook to 4.5%-5.5%.
Henry Schein One Adds a Recurring Growth Engine
Henry Schein One gives HSIC a recurring component alongside its distribution operations. About 90% of its revenues are recurring, and nearly 13,000 customers subscribe to the Dentrix Ascend and Dentally cloud-based platforms.
June set a record for new Dentrix Ascend customers. Those customers generate about $800 in average monthly revenues, versus roughly $500 across Henry Schein One’s broader customer base, supporting a higher-value software mix as adoption grows.
HSIC’s Value Creation Plan Could Lift Profitability
Management continues to target more than $200 million of operating income improvement over the next few years and a $125 million annualized run rate by the end of 2026. The plan is becoming increasingly important to the earnings trajectory.
Initial savings from global outsourcing were expected to begin in the third quarter. For 2026, roughly 60% of in-year operating income improvement is expected from general and administrative savings and 40% from gross profit initiatives.
Image Source: Zacks Investment Research
Henry Schein’s Balance Sheet Raises the Risk Bar
HSIC ended the second quarter with $157 million in cash and cash equivalents, compared with $138 million of current debt maturities and $2.30 billion of long-term debt. Interest expense rose to $43 million from $39 million in the first quarter.
Inflation, tariffs, freight and energy costs add pressure, while larger dental support organizations can negotiate more aggressively on pricing and rebates. Dentsply Sirona Inc. (XRAY - Free Report) , a major dental-products and technology company, underscores the competitive intensity across dental markets.
McKesson Corporation (MCK - Free Report) is another large healthcare distribution company serving providers with medical products and services. Its scale illustrates the broader competitive environment in healthcare distribution, where purchasing power and execution discipline matter.
HSIC Trades Below Key Market Valuation Benchmarks
HSIC trades at 15.60X forward 12-month earnings, below 17.53X for its Zacks sub-industry, 21.10X for the Zacks Medical sector and 20.63X for the S&P 500. That discount offers some valuation support.
Image Source: Zacks Investment Research
The stock is not cheap against its own recent history. Its forward multiple remains above the five-year median of 14.41X, so investors are still paying more than HSIC’s typical valuation despite the discount to broader benchmarks.
HSIC’s Style Scores Support a Selective Approach
The bottom line is that HSIC has more fundamental support than it did earlier in the year, but the case still depends on execution. Broader sales growth, recurring technology revenues and planned savings are positives, while leverage and margin risks remain.
HSIC currently carries a Zacks Rank #3 (Hold), with a Value Score of A, Growth Score of B and Momentum Score of F. The combination favors investors focused on valuation and improving growth characteristics, but the weak Momentum Score argues for selectivity rather than treating the stock as an uncomplicated buy.
View the Zacks #1 Rank List
Image: Bigstock
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
Key Takeaways
Henry Schein, Inc. (HSIC - Free Report) is showing broader growth and a better earnings outlook, but the investment case is not free of execution risk. Second-quarter gains spanned distribution, specialty products and technology, while management raised its 2026 sales and earnings guidance.
The question is whether that improvement is enough to justify buying now. Relative valuation is supportive, but leverage, customer concentration and a savings plan that is still ramping argue for evidence that margin gains can persist.
HSIC’s Core Businesses Are Showing Better Growth
Second-quarter growth was broad. Global Distribution and Value-Added Services sales rose 6.6%, Global Specialty Products increased 8.7% and Global Technology advanced 8.2%. That mix reduces reliance on any single business line to carry the growth story.
Internal growth was also healthy in key areas. Global Distribution and Value-Added Services posted 4.5% internal growth, while Technology delivered 9.1%, helping management lift its 2026 total sales growth outlook to 4.5%-5.5%.
Henry Schein One Adds a Recurring Growth Engine
Henry Schein One gives HSIC a recurring component alongside its distribution operations. About 90% of its revenues are recurring, and nearly 13,000 customers subscribe to the Dentrix Ascend and Dentally cloud-based platforms.
June set a record for new Dentrix Ascend customers. Those customers generate about $800 in average monthly revenues, versus roughly $500 across Henry Schein One’s broader customer base, supporting a higher-value software mix as adoption grows.
HSIC’s Value Creation Plan Could Lift Profitability
Management continues to target more than $200 million of operating income improvement over the next few years and a $125 million annualized run rate by the end of 2026. The plan is becoming increasingly important to the earnings trajectory.
Initial savings from global outsourcing were expected to begin in the third quarter. For 2026, roughly 60% of in-year operating income improvement is expected from general and administrative savings and 40% from gross profit initiatives.
Image Source: Zacks Investment Research
Henry Schein’s Balance Sheet Raises the Risk Bar
HSIC ended the second quarter with $157 million in cash and cash equivalents, compared with $138 million of current debt maturities and $2.30 billion of long-term debt. Interest expense rose to $43 million from $39 million in the first quarter.
Inflation, tariffs, freight and energy costs add pressure, while larger dental support organizations can negotiate more aggressively on pricing and rebates. Dentsply Sirona Inc. (XRAY - Free Report) , a major dental-products and technology company, underscores the competitive intensity across dental markets.
McKesson Corporation (MCK - Free Report) is another large healthcare distribution company serving providers with medical products and services. Its scale illustrates the broader competitive environment in healthcare distribution, where purchasing power and execution discipline matter.
HSIC Trades Below Key Market Valuation Benchmarks
HSIC trades at 15.60X forward 12-month earnings, below 17.53X for its Zacks sub-industry, 21.10X for the Zacks Medical sector and 20.63X for the S&P 500. That discount offers some valuation support.
Image Source: Zacks Investment Research
The stock is not cheap against its own recent history. Its forward multiple remains above the five-year median of 14.41X, so investors are still paying more than HSIC’s typical valuation despite the discount to broader benchmarks.
HSIC’s Style Scores Support a Selective Approach
The bottom line is that HSIC has more fundamental support than it did earlier in the year, but the case still depends on execution. Broader sales growth, recurring technology revenues and planned savings are positives, while leverage and margin risks remain.
HSIC currently carries a Zacks Rank #3 (Hold), with a Value Score of A, Growth Score of B and Momentum Score of F. The combination favors investors focused on valuation and improving growth characteristics, but the weak Momentum Score argues for selectivity rather than treating the stock as an uncomplicated buy.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.